Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research[1][2][3].
Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model[1].
Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model[4].
| Animal Model: | Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; 10 mg/kg; 3 times per week |
| Result: | Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells. Repressed PY-STAT3 levels in H1650 cells. Inhibited the growth of tumors with H322 and CAF cells. Inhibited the growth of tumors with H1650 and CAF cells. |
| Animal Model: | Female NOD-SCID mice with MCF-7 tumor[4] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks |
| Result: | Blocked MCF-7 engraftment, induced regressions in 90% of tumors. |
[1]. Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011 Sep 15;71(13):1455-65.
[2]. Khan FA, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12.
[3]. Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul;9(7):974-982.
[4]. Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press). 2016 Feb 3;8:13-27.